Search the Newsreel

HC Wainwright Has Negative Outlook of JANX FY2030 Earnings

HC Wainwright has lowered its FY2030 earnings per share (EPS) estimate for Janux Therapeutics (NASDAQ:JANX) to $0.97, down from $1.06, while the consensus remains a loss of $1.70 per share. This adjustment follows Janux's recent quarterly earnings report, where the company missed analyst expectations …

Janux Therapeutics Inc (JANX) Stock News Today

This article provides an overview of Janux Therapeutics Inc (JANX) stock information, including its current trading price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the platform for users interested in …

Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile

Janux Therapeutics (JANX) saw its stock rise by 7.1% after announcing a narrower net loss for the second quarter and first half of 2026. The company reported a net loss of US$21.97 million, or US$0.35 per share, in Q2 2026, an improvement from US$33.86 …

RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating

RBC Capital Markets has increased its price target for Janux Therapeutics (JANX) to $34 from $30, while reiterating an Outperform rating on the stock. This adjustment reflects RBC's continued positive outlook on the company.

Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results

Janux Therapeutics, Inc. (NASDAQ:JANX) missed its latest quarterly earnings expectations, with revenues significantly lower than forecasts and per-share losses exceeding predictions. As a result, analysts have reduced their revenue estimates for 2026 and increased their loss per share forecasts, though the consensus price target …

Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results

Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating for Janux Therapeutics Inc (JANX) with a price target of $22.00. While other analysts like William Blair also issued a Buy rating, Barclays maintained a Sell rating. The company recently reported a quarterly …

Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside

Janux Therapeutics, Inc.'s average 12-month price target has been slightly reduced by analysts from $33.56 to $33.25, with a range of $14 to $60 per share. Despite the cut, the new target still implies a significant 107% potential upside based on the Aug. 6 …

Janux Therapeutics (NASDAQ: JANX) posts Q2 loss on collaboration revenue

Janux Therapeutics reported a Q2 2026 net loss of $22.0 million, narrowing from $33.9 million a year prior, driven by $10.3 million in collaboration revenue from its Bristol-Myers Squibb agreement. For the first half of 2026, the company recorded $14.0 million in collaboration revenue …

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics reported its financial results for the second quarter of 2026, highlighting continued progress across its clinical programs, including JANX007, JANX014, and JANX011. The company maintains a strong financial position with $970.9 million in cash and investments and anticipates several key clinical milestones …

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) reported a Q2 loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.26 loss, though it improved from a $0.55 loss a year ago. The company also missed revenue estimates, posting $10.27 million against an expectation of …

Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates

Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M

Janux Therapeutics, Inc. (JANX) reported its Q2 revenue at $10.3 million, falling short of the FactSet estimate of $19.1 million. The article also mentions other recent news concerning the company, including a report of earnings results for the second quarter and six months ended …

BRIEF-Janux Therapeutics Q2 Basic EPS USD -0.35

Janux Therapeutics reported a Q2 basic EPS of USD -0.35. The article, sourced from Reuters, provides this brief financial update.

Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Gamble with 142% Potential Upside

Janux Therapeutics (JANX) is a clinical-stage biopharmaceutical company focusing on immunotherapies for cancer, showing a potential upside of over 142% according to analysts. Despite negative financial metrics typical of early-stage biotech firms, Janux benefits from strategic collaborations with major pharmaceutical companies and a robust …

Form 4 Janux Therapeutics Inc For: 31 July By Investing.com

This article announces the filing of a Form 4 for Janux Therapeutics Inc. for the period ending July 31. It provides no further details beyond this announcement and includes general market data and related news. The Form 4 filing is a mandatory SEC document …

Janux Therapeutics Inc (JANX) Institutional Confidence

Janux Therapeutics Inc (JANX) has an institutional shareholding score of 10.00, ranking 1st in its industry. The institutional shareholding proportion increased by 0.64% quarter-over-quarter, reaching 110.21%. Steven Cohen is the largest institutional shareholder, though his holdings decreased by 62.25%.

Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis

Janux Therapeutics Inc (JANX) currently holds a financial score of 7.85, ranking 76th out of 384 companies in the Biotechnology & Medical Research industry. The company's financial status is deemed stable, while its operating efficiency is considered average. Key financial metrics such as total …

Janux Therapeutics Inc (JANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Janux Therapeutics Inc (JANX), detailing its price momentum score of 3.51 within the Biotechnology & Medical Research industry. It identifies current support at $14.46 and resistance at $16.80, suggesting suitability for range-bound swing trading. The analysis also …

Understanding Momentum Shifts in (JANX)

An analysis of Janux Therapeutics Inc. (NASDAQ: JANX) indicates weak sentiment across all time horizons, supporting a short bias. The article identifies a mid-channel oscillation pattern and highlights an exceptional 99.0:1 risk-reward short setup targeting a 29.8% downside. AI-generated trading strategies are provided for …

Janux Therapeutics, Inc. Revenue Breakdown – NASDAQ:JANX

Janux Therapeutics, Inc. (NASDAQ:JANX) generated $10.00 million USD in revenue last year, primarily from its Novel Immunotherapies segment, which also contributed $10.00 million USD in revenue. The United States was its largest geographical contributor, also accounting for $10.00 million USD in revenue in the …

Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Janux Therapeutics Inc (JANX), noting its current valuation score of 7.63, which ranks it 208 out of 384 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -8.12, comparing it to recent …

Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Thursday

Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides information regarding Janux Therapeutics Inc (JANX) stock, focusing on its dividend and stock split history. It states that the company has not distributed any dividends over the past five years. Key financial data like market cap and current stock price are …

JANX|Janux Therapeutics Inc|Price:15.635|Chg%:+0.305

Janux Therapeutics Inc (JANX) has a TradingKey Stock Score of 6.70/10, indicating relatively healthy fundamentals and high growth potential, though its valuation is only considered fair. The company specializes in developing tumor-activated immunotherapies for cancer, with significant revenue and profit growth. Analysts have a …

Janux Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

Janux Therapeutics Inc. (JANX) is a clinical-stage biopharmaceutical company focused on developing tumor-activated immunotherapies for cancer using its TRACTr and TRACIr platforms. The company's clinical candidates, JANX007 and JANX008, target prostate cancer and various solid tumors respectively. The article provides an overview of the …

Janux Therapeutics Inc (JANX) Income Statement

This article presents the quarterly and annual income statements for Janux Therapeutics Inc. (JANX), detailing revenue, operating expenses, research and development costs, and net income figures. It provides insights into the company's financial performance and efficiency over various fiscal periods, alongside a FAQ section …

Janux Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Barrett Ronald W

This article is a statement of changes in beneficial ownership of securities for Director Ronald W. Barrett of Janux Therapeutics. It is identified as a Form 4 filing, which indicates a required disclosure of stock transactions by company insiders. The full content is described …

Avoiding Lag: Real-Time Signals in (JANX) Movement

This article provides a real-time stock analysis for Janux Therapeutics Inc. (NASDAQ: JANX), indicating near-term weak sentiment but mid-term strength within a broader long-term weak bias. It highlights specific resistance and support levels, along with three AI-generated trading strategies: Position Trading, Momentum Breakout, and …